Norwood, MA (PRWEB) May 31, 2012
BioPharm Insight and BioPharm Clinical, Infinata’s flagship intelligence solutions for the global biopharmaceutical community, will again this year be active participants in June’s BIO International Conference and DIA Annual Meeting with new product announcements and hosted networking events.
BioPharm Insight will also have dedicated journalists on-site interviewing key opinion leaders and company executives at each conference about major developments to come over the next 6-12 months. To ensure you receive our post-conference intelligence reports, sign up for our newsletter at biopharminsight.com.
To preview the data and intelligence inside BioPharm Insight and BioPharm Clinical, get a personalized demo and free trial at biopharminsight.com and biopharmclinical.com.
About BioPharm Insight
BioPharm Insight is the definitive guide to the global biopharma community. BioPharm Insight provides clients with an information edge by combining the most comprehensive real-time database of companies, drugs, contacts, M&A and licensing deals, forecasts and clinical trial data with proprietary forward-looking intelligence uncovered by an independent team of investigative journalists months or even years before it breaks in mainstream media. To learn more, visit biopharminsight.com.
About BioPharm Clinical
BioPharm Clinical is an exclusive support solution for clinical operations professions, providing real-time trial analytics and the most comprehensive database of sites and investigators. Clients benefit from proprietary calculations tailored to their particular trial requirements, detailed milestone timelines and more as they make critical study feasibility assessments and evaluate investigators for their global programs. Learn more at biopharmclinical.com.
About Infinata, Inc.
Featuring a comprehensive BioPharm Solutions Suite, unique Wealth Prospecting tools and innovative Custom Data Services, Infinata provides personalized technology solutions to turn information into insight. Infinata is a part of Mergermarket, a Financial Times Group company and a division of Pearson plc. To learn more, visit infinata.com.